MikeTrendsTrends right now

search

pharmaceutical companies

Trends

  1. 1
    Kobayashi Pharmaceutical weighs takeover offer worth over ¥500 billion●Kobayashi Pharmaceutical, the firm that was at the center of a supplement contamination scandal involving suspected deatMmastodonBusinessMarkets429 min ago

    Kobayashi Pharmaceutical, the Japanese maker at the center of a supplement contamination scandal linked to suspected deaths, is reportedly considering a buyout offer valued at more than ¥500 billion. The possible deal comes as the company continues to face fallout from the scandal, which damaged its reputation and finances.

  2. 2
    European Capital Backs Colombian Biotech Firm to Make 250 Million Vaccines▼Europe Injects Capital into Colombian Biotech Firm to Produce 250 Million Vaccines✉newsWorldEU Politics46 min ago

    European investors are injecting capital into a Colombian biotechnology company with plans to produce 250 million vaccines. The deal signals growing confidence in Colombia's pharmaceutical sector and could expand regional vaccine manufacturing capacity, reducing reliance on imports. Details on the investors, funding amount and timelines have not yet been disclosed.

  3. 3
    Anthropic quietly sets up AI-powered biology lab▼Anthropic creates AI powered wetlabYhnScienceBiology96 h ago

    Anthropic has established its own wet laboratory as it expands its AI-driven drug discovery programme, according to Reuters. The lab will let the company test biological hypotheses generated by its AI models in real experiments. Observers see it as a notable step for an AI firm moving from software into hands-on biology and pharmaceutical research.

  4. 4
    Arrowhead Pharmaceuticals Stock Nears Five-Year High on Phase 3 Win▼ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval✉newsBusinessRetail1 h ago

    Arrowhead Pharmaceuticals shares are on track to reach their highest level in more than five years after positive Phase 3 trial results, with retail investors celebrating the biotech's momentum. The company is reportedly aiming for a broader FDA approval than initially expected, fueling optimism about the commercial potential of its drug pipeline and driving renewed interest in the stock.